Aldeyra Therapeutics, Inc.

NASDAQ:ALDX

6.13 (USD) • At close September 6, 2024
Bedrijfsnaam Aldeyra Therapeutics, Inc.
Symbool ALDX
Munteenheid USD
Prijs 6.13
Beurswaarde 364,254,408
Dividendpercentage 0%
52-weken bereik 1.42 - 7.42
Industrie Biotechnology
Sector Healthcare
CEO Dr. Todd C. Brady M.D., Ph.D.
Website https://www.aldeyra.com

An error occurred while fetching data.

Over Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a

Vergelijkbare Aandelen

Mainz Biomed B.V. logo

Mainz Biomed B.V.

MYNZ

0.327 USD

CymaBay Therapeutics, Inc. logo

CymaBay Therapeutics, Inc.

CBAY

32.48 USD

Milestone Pharmaceuticals Inc. logo

Milestone Pharmaceuticals Inc.

MIST

1.46 USD

Rhythm Pharmaceuticals, Inc. logo

Rhythm Pharmaceuticals, Inc.

RYTM

49.25 USD

Beyond Air, Inc. logo

Beyond Air, Inc.

XAIR

0.41 USD

Co-Diagnostics, Inc. logo

Co-Diagnostics, Inc.

CODX

1.34 USD

Fusion Pharmaceuticals Inc. logo

Fusion Pharmaceuticals Inc.

FUSN

21.55 USD

Profound Medical Corp. logo

Profound Medical Corp.

PROF

8.2 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)